Evidence map›Paper›PMID 32483681›Full record

ArticleDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2020

Design and evaluation of a novel nanodrug delivery system for reducing the side effects of clomiphene citrate on endometrium.

Marziyeh Ajdary, Fariborz Keyhanfar, Reza Aflatoonian, Amir Amani, FatemehSadat Amjadi, Zahra Zandieh, Mehdi Mehdizadeh

Open access · greenAbstract read
In one paragraph

Article in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Marziyeh AjdaryCellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.
Fariborz KeyhanfarDepartment of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Reza AflatoonianDepartment of Endocrinology and Female Infertility, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.
Amir AmaniNatural Products and Medicinal Plants Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran.
FatemehSadat AmjadiDepartment of Anatomical Science, Iran University of Medical Sciences, Tehran, Iran.
Zahra ZandiehDepartment of Anatomical Science, Iran University of Medical Sciences, Tehran, Iran.
Mehdi MehdizadehCellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran. mehdizadeh.m@iums.ac.ir.
Iran University of Medical Sciences · IRRoyan Institute · IRTehran University of Medical Sciences · IR

Funding

Iran University of Science and Technology 94-05-117-27524
6 · The paper itself

Abstract

backgroundStimulation of ovulation with clomiphene citrate can cause side effects on endometrial receptivity. Formulation with nano-size may be an alternative therapy for women with ovulatory disorders. In this study, we investigated sustained-release clomiphene citrate by using Phosal-based formulation (PBF) and evaluate its decreased side effect on the endometrial receptivity.

methodsIn the in-vitro study, CC loaded PBF was analyzed using Zetasizer, Fourier-transform infrared spectroscopy (FTIR), and Transmission electron microscopy (TEM). In the in-vivo study, 24 female mice were randomly divided into three groups: CC (5 mg/kg), CC/PBF (5 mg/kg) and SS (1 ml) daily administered and injected with 5 IU HCG and mated after two days. At day 4.5, pregnant mice were euthanized and endometrial tissue was extracted for quantitative polymerase chain reaction (Q-PCR) analysis.

resultsThe optimized PBF contained Phosal 50PG/glycerol in a 2:8 ratios (w/w) and the particle size of optimum formulation was 67 ± 0.30551 nm and the release of CC from CC-containing PBF was slightly faster in the first 24 h; wherein, 29% of CC was released, and 76% of CC was released up to 120 h. The mRNA levels of leukemia inhibitory factor (LIF), leukemia inhibitory factor receptor alpha (LIFR), HOXA10, Heparin-binding epidermal growth factor (HB-EGF), and epidermal growth factor (EGF) were significantly upregulated and MUC1 and PGR mRNA levels were significantly downregulated in the CC-containing PBF-treated animals compared with only CC group (P < 0.05).

conclusionSustained release formulation of clomiphene citrate increased its targeting efficiency and improved the impact of the CC on implantation. Graphical abstract A new Phosal Based Formulation (PBF) was designed to decrease the side effects of Clomiphene citrate (CC) on endometrium. This drug formulation could react better during implantation by increasing the expression of genes involved in implantation. The in vivo study demonstrated that the CC-containing PBF in mice has a significantly higher endometrial receptivity, compared with the suspension.

Indexed as

AnimalsClomipheneDelayed-Action PreparationsDrug CompoundingDrug Delivery SystemsEndometriumFemaleFertility Agents, FemaleGene Expression ProfilingGene Expression RegulationGenetic MarkersMiceModels, AnimalNanoparticlesParticle SizePregnancyClomipheneDelayed-Action PreparationsFertility Agents, FemaleGenetic MarkersClomiphene citrateEndometrial receptivityPhosal-based formulationSustained release

Identifiers

PMID32483681
PMCPMC7704853
OpenAlexW3032860922

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.